Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Clavel, Sylvaine
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	Recruiting	3	905	Europe, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 1 Diabetes, Obesity, Overweight	05/27	05/27
SURPASS-T1D-2, NCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	Not yet recruiting	3	465	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 1 Diabetes, Obesity, Overweight	04/27	12/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
SEECLOOP, NCT06363916: Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System	Recruiting	N/A	160	Europe	Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation	Medtrum France, Axonal-Biostatem	Type 1 Diabetes	11/25	12/25
PDF, NCT04533152: Prognostic Determinants in Patients With Diabetic Foot Ulcer.	Recruiting	N/A	1000	Europe, RoW		University Hospital, Bordeaux, Fondation Francophone pour la Recherche sur le Diabete	Diabetic Foot Ulcer	11/29	11/29

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Clavel, Sylvaine
SURPASS-T1D-1, NCT06914895: A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight	Recruiting	3	905	Europe, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 1 Diabetes, Obesity, Overweight	05/27	05/27
SURPASS-T1D-2, NCT06962280: A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight	Not yet recruiting	3	465	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Type 1 Diabetes, Obesity, Overweight	04/27	12/27
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
SEECLOOP, NCT06363916: Evaluation of Security and Efficacy of Medtrum Hybrid Closed Loop System	Recruiting	N/A	160	Europe	Insulin Management System in Manual mode of operation, Insulin Management System in Automatic mode of operation	Medtrum France, Axonal-Biostatem	Type 1 Diabetes	11/25	12/25
PDF, NCT04533152: Prognostic Determinants in Patients With Diabetic Foot Ulcer.	Recruiting	N/A	1000	Europe, RoW		University Hospital, Bordeaux, Fondation Francophone pour la Recherche sur le Diabete	Diabetic Foot Ulcer	11/29	11/29